Brokerages Set Voyager Therapeutics, Inc. (NASDAQ:VYGR) PT at $17.43

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) has been assigned an average rating of "Buy" from the eight research firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among analysts that have covered the stock in the last year is $17.43.

A number of equities research analysts have commented on VYGR shares. Leerink Partnrs upgraded shares of Voyager Therapeutics to a "strong-buy" rating in a research note on Wednesday, October 16th. StockNews.com lowered shares of Voyager Therapeutics from a "buy" rating to a "hold" rating in a report on Friday. Wedbush cut their price objective on shares of Voyager Therapeutics from $8.00 to $7.00 and set a "neutral" rating for the company in a report on Wednesday, August 7th. HC Wainwright reaffirmed a "buy" rating and set a $30.00 price objective on shares of Voyager Therapeutics in a report on Thursday. Finally, Leerink Partners assumed coverage on shares of Voyager Therapeutics in a report on Wednesday, October 16th. They set an "outperform" rating and a $15.00 price objective for the company.

Insider Activity at Voyager Therapeutics

In related news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the firm's stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total value of $34,914.18. Following the completion of the transaction, the insider now directly owns 86,001 shares of the company's stock, valued at approximately $500,525.82. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.53% of the stock is currently owned by insiders.

Institutional Trading of Voyager Therapeutics

Institutional investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. lifted its position in shares of Voyager Therapeutics by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company's stock worth $61,000 after purchasing an additional 4,098 shares during the last quarter. Patriot Financial Group Insurance Agency LLC lifted its position in shares of Voyager Therapeutics by 7.0% during the third quarter. Patriot Financial Group Insurance Agency LLC now owns 136,894 shares of the company's stock worth $801,000 after purchasing an additional 9,000 shares during the last quarter. Hunter Perkins Capital Management LLC lifted its position in shares of Voyager Therapeutics by 3.3% during the third quarter. Hunter Perkins Capital Management LLC now owns 64,040 shares of the company's stock worth $375,000 after purchasing an additional 2,025 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Voyager Therapeutics by 6.0% during the second quarter. The Manufacturers Life Insurance Company now owns 94,398 shares of the company's stock worth $747,000 after purchasing an additional 5,365 shares during the last quarter. Finally, Armistice Capital LLC lifted its position in shares of Voyager Therapeutics by 11.3% during the second quarter. Armistice Capital LLC now owns 5,200,000 shares of the company's stock worth $41,132,000 after purchasing an additional 528,000 shares during the last quarter. 48.03% of the stock is currently owned by institutional investors.

Voyager Therapeutics Trading Up 4.0 %

NASDAQ VYGR traded up $0.27 on Monday, reaching $7.02. 531,282 shares of the stock were exchanged, compared to its average volume of 644,713. Voyager Therapeutics has a one year low of $5.71 and a one year high of $11.72. The firm has a market capitalization of $381.85 million, a PE ratio of -140.40 and a beta of 0.91. The company's 50-day simple moving average is $6.56 and its two-hundred day simple moving average is $7.59.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last released its earnings results on Tuesday, August 6th. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.38) by $0.20. Voyager Therapeutics had a net margin of 6.28% and a return on equity of 3.31%. The company had revenue of $29.58 million for the quarter, compared to analysts' expectations of $11.52 million. During the same quarter last year, the business earned ($0.51) EPS. Sell-side analysts forecast that Voyager Therapeutics will post -1.27 earnings per share for the current fiscal year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.